Amyotrophic Lateral Sclerosis also known as Lou Gehrig’s disease and motor neuron disease, is a neurodegenerative disease, affecting nerve cells in the brain and spinal cord that controls voluntary muscles. The disease is progressive in nature, meaning it gets worse over time.
According to a study published in Centers for Disease Control and Prevention, in 2016, around 14,713 people were diagnosed with ALS in the U.S. and prevalence rate of ALS was 4.7 cases per 100,000 people in 2012. The prevalence rate increased to 5.0 cases per 100,000 people and around 15,908 people were diagnosed with ALS in 2013, according to the same study. The increasing prevalence of ALS is in turn, expected to support growth of the Amyotrophic Lateral Sclerosis (ALS) Treatment Market in the near future.
Major Players in the Amyotrophic Lateral Sclerosis Treatment Industry:
1) Mitsubishi Tanabe Pharma
Mitsubishi Tanabe Pharma is a Japanese pharmaceuticals company, a subsidiary of Mitsubishi Chemical Holdings Corporation. Mitsubishi Pharma Corporation, develops, manufactures, procures, and commercializes ethical drugs and over the counter pharmaceutical products. Mitsubishi Tanabe Pharmaceuticals developed the first BET inhibitor molecules.
The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system disorders, and others. The company was founded in the year 1678, and the headquarters are located in Doshomachi, Osaka, Japan.
2) Takeda Pharmaceuticals
Takeda Pharmaceuticals is a Japanese multinational pharmaceutical company. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Takeda was founded in the year 1781, and the headquarters are located in Nihonbashi, Tokyo, Japan.
In December 2022, the company announced it would acquire Nimbus Lakshmi, Inc. and its lead compound NDI-034858 which is an allosteric TYK2 inhibitor, from Nimbus Therapeutics, LLC for up to U.S. $6 billion.
3) Mylan N.V.
Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Products manufactured include Generic and Specialty pharmaceuticals and active pharmaceutical ingredients. The company was founded in the year 1961, by Milan Puskar and Don Panoz. The headquarters were located in Canonsburg, Pennsylvania, U.S.
As of April 2021, The Company announced, it had received approval for its bio similar of Humira, a drug used to treat a range of autoimmune diseases, from the European Commissions.
4) Sanofi S.A.
Sanofi S.A. is a multinational pharmaceutical company that engages in the research and development, of pharmacological products, in the prescription market. The firm cover therapeutic areas like Cardiovascular, central nervous system, diabetes, internal medicine. The company was founded in 973 and the headquarters are located in Paris, France. Products manufactured include Medications, Genetic drugs, Vaccines, Animal Health, etc.
In December, 2022 Sanofi expanded its collaboration with Innate Pharma, with Sanofi licensing a natural killer (NK) cell nagger program targeting B7H3 from Innate’s ANKET platform.
